Fundraising FoxNuvOx Pharma
4 known investors
Find your way into NuvOx Pharma
Sign up to see every warm intro you have to NuvOx Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NuvOx Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NuvOx Pharma is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen delivery from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radiosensitizer), stroke, and respiratory distress.
Investors · 4
How we know: MEDA Angels's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $301.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $478.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $144K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $317.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $298.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $297.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $243.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $204.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does NuvOx Pharma do?
- NuvOx Pharma is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen delivery from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radiosensitizer), stroke, and respiratory distress.
- Who are NuvOx Pharma's investors?
- NuvOx Pharma's investors include Band of Angels, MEDA Angels, Hunniwell Lake Ventures LLC, Pasadena Angels.